INFLAMMATORY GENE EXPRESSION IN WOMEN DIAGNOSED WITH POLYCYSTIC OVARIAN SYNDROME by Taylor, Myles K
Pittsburg State University 
Pittsburg State University Digital Commons 
Electronic Thesis Collection 
Winter 12-6-2016 
INFLAMMATORY GENE EXPRESSION IN WOMEN DIAGNOSED 
WITH POLYCYSTIC OVARIAN SYNDROME 
Myles K. Taylor 
Pittsburg State University, mtaylor@gus.pittstate.edu 
Follow this and additional works at: https://digitalcommons.pittstate.edu/etd 
 Part of the Endocrine System Diseases Commons, Endocrinology Commons, Immunopathology 
Commons, Molecular Biology Commons, and the Translational Medical Research Commons 
Recommended Citation 
Taylor, Myles K., "INFLAMMATORY GENE EXPRESSION IN WOMEN DIAGNOSED WITH POLYCYSTIC 
OVARIAN SYNDROME" (2016). Electronic Thesis Collection. 224. 
https://digitalcommons.pittstate.edu/etd/224 
This Thesis is brought to you for free and open access by Pittsburg State University Digital Commons. It has been 
accepted for inclusion in Electronic Thesis Collection by an authorized administrator of Pittsburg State University 










INFLAMMATORY GENE EXPRESSION IN WOMEN DIAGNOSED WITH 








A Thesis Submitted to the Graduate School 
in Partial Fulfillment of the Requirements 
for the Degree of 
































INFLAMMATORY GENE EXPRESSION IN WOMEN DIAGNOSED WITH 
























Thesis Advisor         ___________________________________________ 
 Dr. Peter Chung, Department of Biology 
 
 
Committee Member ___________________________________________ 
 Dr. Neal Schmidt, Department of Biology 
 
 
Committee Member ___________________________________________ 
 Dr. Barbara McClaskey, Department of Nursing 
 
 iii 
INFLAMMATORY GENE EXPRESSION IN WOMEN DIAGNOSED WITH 
POLYCYSTIC OVARIAN SYNDROME 
 
 
An Abstract of the Thesis by 
Myles K Taylor 
 
 
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women 
of reproductive age. The pathophysiology of PCOS has conventionally thought to 
originate from androgen excess. However, recent evidence suggests that androgen excess 
is a downstream consequence to inflammatory dysregulation and subsequent metabolic 
abnormalities. Inflammatory mRNA gene expression of TNF and IL-1ß in mononuclear 
cells isolated from women diagnosed with PCOS was explored using qPCR. Also, the 
correlations between body mass index (BMI) and fasting glucose on mRNA expression 
of TNF and IL-1ß were explored. mRNA expression of both TNF and IL-1ß were 
found to be significantly higher in PCOS subjects (P<0.01). BMI was found to 
significantly increase mRNA expression of TNF and IL-1ß (P<0.05). However, only 
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Polycystic Ovarian Syndrome 
Polycystic ovarian syndrome (PCOS), first identified in 1935 by Dr. Stein and 
Leventhal, is a common endocrine disorder affecting women of childbearing years [1]. 
Approximately 4 to 7 percent of women are affected. Women affected by PCOS are more 
likely to receive care for heart disease, diabetes, and mental health conditions. $4.36 
billion dollars are spent annually on the care for women with PCOS [2]. Currently, the 
etiology of PCOS is poorly understood. However, recent literature has suggested 
inflammatory dysregulation in mononuclear cells (MNC) plays a significant role in the 
early stages of PCOS. 
 Clinical manifestations associated with PCOS are very broad and are not limited 
gynecological issues. Diagnosis of PCOS is highly disputed among medical professions 
due to several similarities with other pathologies. No single definitive diagnostic test 
exists for PCOS, rather, a collective of physical and biochemical signs is considered for 
diagnosis. Rotterdam criteria (Table 1) are the most commonly used guidelines for 
diagnosis of PCOS [3-5]. Obesity and insulin resistance, although not considered 
diagnostic criterion of PCOS, are highly prevalent among women with PCOS, and 
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contribute long-term health risks such as cardiovascular disease, type 2 diabetes, and 
dyslipidemia [3, 4, 6].  
 
Rotterdam Criteria 2003 
1. Oligo-and/or anovulation 
2. Clinical and/or biochemical signs of hyperandrogenism 
3. Polycystic ovaries 
(Two of three criteria needed) 
Table 1. Rotterdam Criteria 2003 
 
 The majority of physical manifestations experienced in PCOS are the result of 
excess androgen hormones. Hair follicles and sebaceous glands are androgen-dependent 
structures and are commonly affected by the increased androgens in PCOS leading to 
hirsutism, pattern baldness, and acne [5, 7]. 
 PCOS represents a complex pathophysiological model with no single causative 
agent currently determined. Rather, multiple factors contributing to the signature 
biochemical feature of hyperandrogenism. Excess androgens are the main culprit behind 
the majority of clinical features of PCOS [5]. 
 Several abnormalities in ovarian physiology occur in women with PCOS. Anti-
Müllerian hormone (AMH) is secreted by granulosa cells (GC) and plays a significant 
role in folliculogenesis. AMH is commonly elevated in PCOS and arrests the progression 
towards ovulation through inhibition of primodial follicle initiation and sensitivity to 
follicle-stimulating hormone (FSH) [8]. Poor fertility outcomes are in women with PCOS 
due to ovulation inhibition. Chronic absence of ovulation encourages the continual 
endometrial stimulation by estrogen, increasing the risk of endometrial hyperplasia and 
endometrial cancer [6, 9]. 
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 Abnormalities in hypothalamus-hypophysis-ovary axis feedback resulting in 
greater secretion of luteinizing hormone (LH) is another common feature of PCOS. 
Elevated LH stimulates ovarian theca cells (TC) to over synthesize androgens resulting in 
hyperandrogenism. Hypoandrogenism decreases the feedback inhibition of progesterone 
and estradiol leading to greater secretion of LH. Disturbances in feedback mechanisms 
perpetuates a pathophysiological cycle of hyperandrogenism [5, 10]. 
 Although hyperandrogenism is the culprit for the majority of the clinical 
manifestations in PCOS, the primary pathophysiological changes in PCOS are poorly 
understood. Insulin resistance may play an important upstream role in androgen 
dysregulation. In normal populations, insulin resistance is most commonly associated 
with obesity related inflammation. While the majority of women with PCOS are 
classified as obese, a small portion have normal body compositions in addition to insulin 
resistance. Therefore, obesity is most likely not the primary cause of insulin resistance. 
Recent literature has suggested that inflammatory dysregulation in MNCs independent of 
body composition contributes to insulin resistance in PCOS [11, 12]. 
 
Body Composition and Inflammation 
Obesity poses a significant public health risk with nearly 80 million people 
affected in the United States. Approximately 69% of adults are overweight with 35% 
classified as obese. Significant increases in developing chronic diseases such as type 2 
diabetes mellitus, hypertension, and chronic heart disease are associated with obesity. 
Clinical guidelines identify obese individuals as a body mass index 30 kg/m2 [13, 14]. 
The majority of women diagnosed with PCOS have elevated BMI with approximately 
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70% classified as obese. However, there remains a small portion of women with PCOS 
who fall within a normal BMI range [15, 16]. Obesity is well defined as a significant 
inflammatory stimulus and contributor to the development of insulin-resistance and type 
2 diabetes. However, the role of obesity in the pathogenesis of PCOS remains unknown. 
Despite this, it is likely that when obesity is present with PCOS, reproduction, and 
metabolic aberrations are more prevalent [17].  
Unlike the common features of swelling, redness and pain found in an acute 
inflammatory response due to tissue injury, obesity-related inflammation is derived from 
metabolic stimuli and maintained at subacute levels. Substantial differences in 
adipocytokine expression exist between adipose tissue from lean and obese individuals. 
Adipose tissue from obese individuals expressed greater amounts of inflammatory TNF 
and IL-1ß. TNF and IL-1ß are major contributors to the development of glucose 
intolerance and insulin resistance, as well as atherosclerosis [18-20]. Conversely, tissue 
from normal weight individuals expressed greater amounts of cytokines of anti-
inflammatory nature, such as IL-4 [21, 22]. Adipocytokines heavily mediate immune and 
inflammatory responses through epigenetic modifications of hematopoietic cells [23, 24]. 
Macrophage, derived from monocytes, are the potent mediators of inflammation 
through the secretion of cytokines. Two major phenotypes of macrophages exist, 
inflammatory M1 phenotype and anti-inflammatory M2 phenotype. Though, this view is 
simplistic. Depending on the signaling environment, individual macrophage exhibit 
various degrees of inflammatory and anti-inflammatory nature, and must be sustained in 
a similar environment to exhibit that phenotype. In obese individuals, increased 
expression of inflammatory cytokines in adipose tissue promotes the M1 phenotype. 
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Consequently, a shift towards the M1 phenotype increases the inflammatory environment 
through the increased production of inflammatory cytokines. Whereas, adipose tissue 
from lean individuals expresses an anti-inflammatory environment, shifting towards the 
M2 phenotype. By producing cytokines of anti-inflammatory nature, M2 macrophage 
maintain an anti-inflammatory environment [25-29]. Interestingly, M1 and M2 
macrophage phenotypes have different preferred energy substrates. Glucose is the 
primary substrate used by M1 macrophages. M2 macrophage prefers fatty acids as an 
energy substrate. Also, macrophages primarily use insulin-independent glucose 
transporters despite having a functional insulin receptor. Insulin-independent glucose 
uptake becomes interesting when insulin resistance and hyperglycemia are present, and 
uptake and utilization of glucose remain normal in macrophage [25, 30-32]. 
 
Inflammation and Insulin Resistance 
Inflammation is well understood to be a major contributor to the development of 
insulin resistance in insulin-sensitive tissues. Cytokines are capable of acting in an 
endocrine fashion if secreted into the blood stream. As obesity increases and subsequent 
cytokine production increases, inflammatory mediators can enter the blood stream and 
travel to peripheral tissues leading to insulin resistance within insulin sensitive tissues. Of 
particular interest, the cardinal inflammatory cytokine TNF has been shown to directly 
inhibit proper insulin signaling through interactions with insulin receptor substrate-1 
(IRS-1). Binding of TNF to the TNF receptor leads the activation of JNK and IKK and 
subsequent phosphorylation of IRS-1 serine residues. Consequently, the IRS-1 function is 
decreased, decreasing the activation of phosphoinositide 3-kinase (PI3K) [33-35]. 
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Decreased activity of PI3K results in the inhibition of protein kinase B (Akt2), which is 
responsible for the translocation of the insulin-dependent glucose transporter GLUT-4. 
Under normal insulin signaling, Akt leads to the suppression of gluconeogenesis through 
inhibition of FoxO1. When abnormal signaling occurs, and Akt activation decreases, 
FoxO1 functions normally and gluconeogenesis continues. Consequently, plasma glucose 
begins to rise as gluconeogenesis continues and remains at hyperglycemic concentrations 
due to the decreased uptake of glucose into the cell by GLUT-4 [36].  
Maintaining a hyperglycemic state has several consequences to various tissues. 
Most notably are the destruction of pancreatic ß-cells which are responsible for the 
production of insulin. As a compensatory mechanism, hyperglycemia stimuli signal ß-
cells to increase the production and secretion of insulin. If this is allowed to continue, ß-
cells will eventually die, leading to type 2 diabetes mellitus and the necessity of 
supplying exogenous insulin. 
Hyperglycemia also contributes to promoting an inflammatory state through the 
preferred bioenergetic pathway of M1-like macrophages. Despite the presence of insulin-
resistance, uptake of glucose by M1-like macrophages is maintained through insulin-
independent transporters and used as an energy substrate in mitochondrial respiration. 
Reactive oxygen species is a strong signal for transcription of inflammatory mediators 
and is primarily produce from NAPDH oxidase during mitochondrial respiration. 
Consequently, another source of inflammation is added and contributes to the cyclical 





Insulin and Hyperandrogenism  
Insulin, in addition to glucose homeostasis, regulates GnRH and LH secretion 
from the pituitary and transcription of the androgen synthesizing enzymes in the ovaries. 
While insulin resistance and hyperinsulinemia develops in peripheral tissues, the pituitary 
and ovaries remain highly sensitive to insulin in PCOS. Increased LH secretion 
consequently augments steroid synthesis in the ovaries. In the ovaries, physiological 
doses of insulin are capable of inducing synthesis of androgens though increase acute 
steroidogenic regulatory protein (StAR) in women with PCOS. Much larger doses of 
insulin are required to elicit the same response in normal women [38-40]. Insulin also 
increases the activity of 17--hydroxylase/17,20-lyase, 3-ß-hydroxysteroid 
dehydrogenase, and aromatase leading to excess production of progesterone, 17--
hydroxyprogesterone, and testosterone [5, 41]. 
 
Body Composition-Independent Inflammation in PCOS 
Obesity is a significant promoter of inflammation and insulin-resistance. 
However, recent studies show that women with PCOS demonstrate elevated 
inflammatory markers and insulin resistance independent of obesity. Compared to BMI-
matched controls, women with PCOS have higher circulating levels of TNF and IL-1ß. 
However, when obesity is present with PCOS, these cytokines are elevated to a greater 
degree [11, 12, 42]. Distribution and physiology of adipose tissue may provide an 
explanation for increased inflammatory markers and insulin resistance in normal weight 
women with PCOS. A large DXA population study found that women with PCOS 
preferentially store visceral adipose in the abdominal region, leading to increased android 
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adiposity in normal weight women. Increased android fat mass in normal weight women 
with PCOS positively correlated with serum insulin and androgens [15, 43]. However, 
increased android adiposity cannot explain insulin resistance and increased inflammation 
in all PCOS cases, particularly lean women. 
 Insulin resistance and increased inflammation in the absence of excess adiposity 
is found in lean women with PCOS, suggesting inflammation is not originally derived 
from adipose tissue. Rather, evidence suggests that the inflammatory response is nutrient-
induced. Mononuclear cells (MNC) were isolated from lean and obese women with 
PCOS and their matching controls during a glucose tolerance test. IL-6, TNF, and IL-1ß 
were assayed from MNC after culturing for 24hr. MNC from both lean and obese women 
with PCOS were found to secrete greater amounts of IL-6, TNF and IL-1ß compared to 
their counterparts. The similar inflammatory response was observed when challenged 
with lipids rather than glucose [11, 12, 44]. 
 Utilizing glucose tolerance testing provides a practical in vivo model simulating 
daily nutrient intake. However, the inflammatory cytokines were assayed from cell 
culture supernatant after culturing for 24hr. Assaying cytokines in this ex vivo fashion 
does not completely represent the inflammatory response of the individual. Also, only 
secreted cytokines were assayed, and does not take into account intracellular cytokines. 
Although, the observed increase in cytokine production among PCOS groups compared 







Due to poor understanding of underlying pathogenesis, therapeutic options are 
limited for PCOS. Treatment is often limited to lifestyle modifications, insulin sensitizing 
agents, and oral contraceptives. Diet and exercise for weight loss are the first choice for 
overweight and obese individuals. However, diet and exercise as a monotherapy has very 
limited efficacy. Metformin, commonly used for type 2 diabetes, is used to treat insulin 
resistance in PCOS. Yet, long-term efficacy is poor [45]. Contraceptives containing 
estrogen and progestin derivatives are commonly prescribed to treat symptoms of excess 
androgens. However, use of hormonal contraceptives come with several unwanted side 
effects, including limiting the ability to conceive [6]. 
 
Purpose of this Research 
 Polycystic ovarian syndrome represents a complex pathophysiological model of 
cyclical nature. Poor understanding of PCOS pathophysiology has greatly limited 
therapies available to clinicians. Previous work exploring inflammatory cytokine 
expression in PCOS have been limited to post translation analysis The objective of this 
study is to evaluate transcriptional mRNA expression of inflammatory cytokines TNF 



















 Thirty-nine women, 25 with PCOS (5 non-obese, 20 obese) and 14 without PCOS 
(9 non-obese, 5 obese), 18-55 years of age volunteered for this study. Non-obese and 
obese were defined as having a BMI of <30 and >30 kg/m2, respectively. Subjects were 
enrolled through the medical practice of Patricia Sullivan, NP-C. All study subjects were 
screened using Rotterdam criteria. PCOS subjects were selected by meeting two of the 
criteria in Table 1. Control subjects had normal ovulation and did not exhibit physical 
manifestations of excess androgens. Subjects taking medications for metabolic conditions 
were excluded from the study. The Pittsburg State University Institutional Review Board 
provided approval for the study. Informed consent was obtained from all participants 
prior to sample collection. 
 
Body Composition 
Height and body weight were recorded with a height rod and beam scale. Height 
was measured to the nearest 1.0 in and body weight was measured to the nearest 1.0 lb. 





After a 12 hour overnight fast, 24 mL of blood was obtained from an antecubital 
vein to measure serum glucose and to isolate MNCs. Twenty mL of blood was treated 
with K2 EDTA to prevent coagulation for isolation of MNCs. The remaining 4 mL of 
blood was allowed to clot and centrifuged at 1,000 x g for 10 minutes to remove the clot. 
Fasting serum glucose was determined by hexokinase G-6-PDH methodology (Mag Lab 
Medical Laboratory, Pittsburg, KS). MNC relative gene expression of TNF and Il1ß 
was determined by quantitative polymerase chain reaction (qPCR) and SYBR green 
chemistry. 
  
Mononuclear Cell Isolation 
Immediately after collection, uncoagulated blood samples were diluted with an 
equal volume of phosphate buffered saline (PBS), inverted several times to mix 
thoroughly. Diluted blood was then carefully layered upon Lymphoprep density gradient 
media and centrifuged at 10˚C for 30 minutes at 800 x g with the brake off. The buffy 
coat containing mononuclear cells was collected and washed with PBS. Mononuclear 
cells were pelleted at 10˚C for 10 minutes at 1200 x g. The PBS supernatant was removed 
and the remaining cell pellet was lysed in 1 mL of TRI-Reagent BD (MRC) and 
transferred to a 1.7 mL microfuge tube. 
 
RNA Isolation 
Before isolating RNA, benchtop and pippettors were thoroughly cleaned and 
treated with RNase Away (Ambion). Phase separation was performed by adding 200 µL 
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of chloroform, mixed vigorously by hand for 15 seconds and centrifuged at 4˚C for 15 
minutes at 12,000 x g. 400 µL of the RNA containing aqueous layer was removed and 
transferred to a new 1.7 microfuge tube. An equal volume of 99% ethanol was added to 
the aqueous layer and transferred to a Direct-Zol (Zymo Research) RNA isolation 
column. All centrifugation steps were performed at 12,000 x g. The column was 
centrifuged for 30 seconds, discarding the flow through. 400 µL of RNA wash was added 
to the column and centrifuged for 30 seconds, discarding the flow though. The column 
was transferred to a new collection tube. An on column DNA digest was performed to 
remove residual gDNA with DNase I for 15 minutes. 400 µL of preRNA wash was added 
to the column and centrifuged for 30 seconds, discarding the flow. This step was 
performed for a second time. 700 µL of RNA wash was added and centrifuged for 1 min. 
The Direct-zol column was then transferred to a microfuge tube. 50 µL of nuclease free 
water was added to the column matrix and incubated for 1 minute and centrifuged for 1 
minute. RNA concentration and purity was quantified with a NanoDrop lite analyzer. 
Isolated total RNA was stored at -80˚C.  
RNA integrity was determined by gel electrophoresis right before cDNA 
synthesis. Five µL of isolated total RNA was heated to 95˚C for 1 min and immediately 
put on ice. A 1.2% agarose gel was made by heating 0.6 g of agarose in 50 mL of 1x 
TAE buffer. 2 µL of ethidium bromide was added to the mixture. The solution was then 
poured into a casting tray to solidify. After solidifying, the agarose gel was transferred to 
an electrophoresis chamber and the chamber was filled with 1x TAE buffer until covering 
the top of the agarose gel. Five µL of 6x loading dye was added to each RNA sample and 
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loaded into the agarose gel. Electrophoresis was performed at 90V for 30 minutes. The 
gel was then imaged on a FluroChem E under UV light.  
 
cDNA Synthesis 
cDNA was synthesized from 2 µg of isolated total RNA using SuperScript IV 
VILO master mix (Invitogen). SuperScript IV VILO contains a mixture of oligo-dT and 
random hexamers. 4 µL of SuperScript IV VILO master mix, variable volume of 
template RNA for 2 µg of total RNA, and variable volume of nuclease free H2O to bring 
the final volume to 20 µL. Reaction was thoroughly mixed by pipetting. Thermal cycling 
condition were 25˚C for 10 minutes, 50˚C for 10 minutes, and 85˚C for 5 minutes. 
Synthesized cDNA was diluted with nuclease free water to obtain a concentration of 10 
ng/µL and separated in several aliquots to prevent multiple freeze thaw cycles. Diluted 
cDNA samples were stored at -20˚C. 
 
Primer Design and Kinetics Validation 
Primers for TNF, IL-1ß, TBP, and SDHA were selected based on product size, 
exon spanning, and primer annealing temperatures above 60˚C. Selected primer 
sequences were analyzed by Primer-Blast (NCBI) for specificity and amplicon size. 
Sequences and product sizes are shown in Table 2. Primers were synthesized by 
Integrated DNA Technologies and supplied in 100 nmol stock concentration. Several 
aliquots of 10 pmol primer solution were prepared by 1:10 dilution of the 100 nmol stock 







TNF Forward 5’-CCTGCCCCAATCCCTTTATT-3’ 81 bp 
Reverse 5’-CCCTAAGCCCCCAATTCTCT-3’ 
IL-1ß Forward 5’-ATGATGGCTTATTACAGTGGCAA-3’ 132 bp 
Reverse 5’-GTCGGAGATTCGTAGCTGGA-3’ 
TBP Forward 5’-TGCACAGGAGCCAAGAGTGAA-3’ 132 bp 
Reverse 5’-CACATCACAGCTCCCCACCA-3’ 
SDHA Forward 5’-TGGGAACAAGAGGGCATCTG-3’ 86 bp 
Reverse 5’-CCACCACTGCATCAAATTCATG-3’ 
Table 2. Forward and Reverse Primer Sequence and Product Size 
 
A gBlock® Gene Fragment (Integrative DNA Technologies) containing each 
PCR amplicon was synthesized and diluted to 100 pg/mL to serve as a positive control, 
reference sample, and inter-run calibrator. Several aliquots of the synthetic DNA 
template were made to prevent multiple freeze/thaw cycles and stored at -20˚C. Kinetic 
efficiencies for each PCR assay was determined from a sevenfold dilution series of the 
synthetic DNA template. The first concentration of the dilution series was 100 pg/mL. 
Several 1:10 dilutions were made until a final concentration of 0.0001 pg/mL. In a clean 
biosafety cabinet, PCR reactions were prepared by combining 10 µL of PowerUp SYBR 
Green master mix (Invitrogen), 0.4 µL of 10 pmol forward primer, 0.4 µL of 10 µL 
reverse primer, 7.2 µL of nuclease free H2O, and 2 µL of template for a final reaction 
volume of 20 µL. A no template control was prepared by replacing template DNA with 
nuclease free H2O. PCR reactions were prepared in triplicate, pipetted into a 48 well 
qPCR optical plate, and sealed with optical adhesive film. Reaction plates were 
centrifuged at 500 x g for 1 minute to collect reaction mixture and remove bubbles 
formed from pipetting. qPCR was performed using an Applied Biosystems StepOne 
qPCR machine. Thermal cycling conditions were 50˚C for 2 minutes to activate UDG, 
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95˚C for 2 minutes for initial DNA denaturation, followed by 40 cycles of 95˚C for 3 
seconds and an annealing/extension temperature of 60˚C for 30 seconds. SYBR green 
fluoresces was measured after each annealing/extension step. A dissociation melting 
curve was included after the last annealing/extension step. Baseline and threshold Cq 
settings were determined by the Applied Biosystems native software. Reaction replicates 
were averaged and plotted against the log10 of template input. Kinetic efficiencies were 
calculated from the slope of the trend line using eq 1 [46]. 
 
Efficiency = 10(-1/slope) (eq. 1) 
 
After performing a dissociation melting curve, the PCR product was 
electrophoresed on a 3% agarose gel to ensure one product and absence of primer dimer 
formation. 1.5 g of agarose was heated in 50 mL of 1x TAE buffer until boiling. 2 µL of 
ethidium bromide was added and poured into a casting tray to cool. After solidifying, the 
agarose gel was transferred to an electrophoresis chamber and covered in 1x TAE buffer. 
5 µL of 6x loading dye was added to each PCR reaction and loaded into the agarose gel. 
Electrophoresis was performed at 60V for 90 minutes. After electrophoresis, the agarose 
gel was imaged on an FluroChemE under UV light. 
 
Quantitative PCR 
 After assay efficiency was determined, qPCR was performed on cDNA samples 
derived from subject MNCs to determine relative expression of TNF and IL-1ß using 
TBP and SDHA as reference genes to normalize cDNA input. One target was run per 
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PCR run to maximize plate efficiency and conserve reagents. Using the synthetic 
template as a reference sample, positive control, and inter-run calibrator, inter-run 
variance can be accounted for and targets on separate runs can be compared. 
 In a clean biosafety cabinet, PCR reactions prepared by combining 10 µL of 
PowerUp SYBR green master mix, 0.4 µL of forward primer, 0.4 µL of reverse primer, 
7.2 µL of H2O, and 2 µL of sample template for a final volume of 20 µL. A no template 
control was included on each plate. Each reaction was prepared in triplicate, pipetted into 
the 48 well qPCR optical plate, and sealed with optical adhesive film. qPCR optical 
plates were centrifuged at 500 x g for 1 min to collect reaction and remove bubbles 
introduced from pipetting. qPCR was performed using an Applied Biosystems StepOne 
qPCR machine. Thermal cycling conditions were 50˚C for 2 minutes to activate UDG, 
95˚C for 2 minutes for initial DNA denaturation, followed by 40 cycles of 95˚C for 3 
seconds and an annealing/extension temperature of 60˚C for 30 seconds. SYBR green 
fluoresces was measured after each annealing/extension step. A dissociation melting 
curve was included after the last annealing/extension step. Baseline and threshold Cq 
settings were adjusted to Cq threshold determined from primer validation. 
 
Reference Gene Stability and Relative Gene Expression 
 Cq data across fourteen experiments were uploaded into qBase+ 3.0 (Biogazelle) 
to determine reference gene stability and relative gene expression of TNF and IL-1ß. 
Sample replicates with Cq variance of  0.5 were excluded from data analysis. TBP and 
SDHA were used to normalize variance in cDNA input. Assay PCR kinetic efficiencies 




 Data were analyzed by SPSS Statistics (IBM Analytics). Relative gene expression 
data was log transformed to meet normality requirements. One-Way ANOVA was used 
to compare relative gene expression between women with PCOS and control women 
followed by LSD post hoc to compare subgroups. Correlation analysis was performed by 


















Age, BMI, and Fasting Glucose 
 Subjects age, height, weight, and BMI (Appendix 1) were obtained prior to 
collecting sample collection. Fasting glucose (Appendix 1) values and peripheral 
mononuclear cells were obtained after fasting 12 hours prior. BMI was significantly 
(P0.001) different between obese and non-obese subjects regardless of PCOS (Table 3). 
Fasting glucose was similar among all subjects. Age was significantly (P0.001) 
different among all subjects. 
 
 









Age (y) 40±14 31±7 19±2 24±8 
BMI (kg/m) 26±3 43±6 25±2 39±8 
Glucose (mg/dL) 90±3 95±16 89±6 90±2 
Table 3. Age, Body Composition, and Fasting Glucose of Subjects. Values are 
expressed as means ± SD. 
 
Isolated Total RNA Purity and Integrity 
 Total RNA from peripheral mononuclear cells was isolated using phenol-
chloroform phase separation and silica spin column methodology. A NanoDrop Lite 
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spectrophotometer was used to quantify total RNA concentration and purity. Protein 
contamination was minimal with 260/280 nm ratios between 1.8 and 2.0 for all samples. 
Intact 16s and 28s rRNA bands were observed for all samples after separation by 
electrophoresis on a 1.2% agarose gel (Figure 1), indicating minimally degraded RNA 




Figure 1. 1.2% RNA Gel Electrophoresis 
 
Primer kinetic efficiencies 
Replicate Cq values for each dilution were averaged and plotted against the log10 
value of the input DNA amount (Figure 2). PCR kinetic efficiencies (Table 4) were 
calculated from the slope of the trend line using eq 1. All assays fell between 86-93% 
efficiency. Linearity (R20.999) was observed for each assay across the dilution series 
 
 20 
indicating PCR inhibitors were minimal. Dissociation curve analysis (Figure 3) revealed 
a single melting peak for each assay representing a single PCR product. Gel 
electrophoresis (Figure 4) further indicated a single PCR product and the absence of 







Figure 2. Correlation of Cq and DNA Input Amount a, TNF R20.999 b, IL-1ß 
























Figure 4. 3% Agarose Gel Electrophoresis of PCR Product 
 
geNorm and qBase+ 
qPCR data across fourteen experiments was uploaded to qBase+. Two sample 
replicates out of 176 were removed for exceeding variance cutoff of >0.5 Cq. Relative 
gene expression of TNF and IL-1ß was quantified by normalizing to reference genes 
TBP and SDHA (Table 5). geNorm analysis (CV=0.198) indicates stability of both 
reference genes across all samples. 
 
Sample TNFa RQ IL-1ß RQ Sample TNFa RQ IL-1ß RQ 
A1 0.46 1.62 A21 0.56 2.86 
A2 0.63 0.63 A22 0.45 1.72 
A3 0.49 0.68 A23 0.59 1.29 
A4 0.63 1.22 A24 0.65 1.33 
A5 0.45 0.49 A25 0.87 1.12 
A6 0.57 1.19 B1 0.41 1.01 
A7 0.66 0.89 B2 0.62 0.90 
A8 0.74 0.82 B3 0.37 0.76 
A9 0.36 0.92 B4 0.41 0.52 
A10 0.30 0.95 B5 0.57 0.48 
A11 0.38 1.40 B6 0.34 0.62 
A12 0.38 0.75 B7 0.40 0.80 
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A13 0.87 1.48 B8 0.38 0.74 
A14 0.62 0.77 B9 0.42 0.86 
A15 0.34 0.70 B10 0.34 0.59 
A16 0.32 0.80 B11 0.26 0.97 
A17 0.55 1.52 B12 0.26 1.01 
A18 0.51 1.06 B13 0.27 0.67 
A19 0.44 0.84 B14 0.31 0.99 
A20 0.39 1.00 
   
Table 5. Relative quantity of TNF and IL-1ß. 
 
 
MNC-derived TNF and IL-1ß expression 
An analysis of variance showed that the effect of PCOS on TNF and IL-1ß 
expression was significant, F(1,37) = 10.866, P=0.002 and F(1,37) = 7.588, P=0.009 
respectively (Figure 5). A post hoc LSD test (Figure 6) showed a significant (P=0.003) 
difference between non-obese controls and obese PCOS, non-obese PCOS and obese 
controls were not significantly different from the other groups. 
 
a b 
Figure 5. Mononuclear Cell Cytokine Expression. Relative quantity of a, TNF and b, 
IL-1ß from fasting samples. Significantly greater expression of TNF (P=0.002) and IL-





Figure 6. Mononuclear Cell Cytokine Expression. Relative quantity of a, TNF and b, 
IL-1ß from fasting samples. Expression of IL-1ß is significantly different between non-
obese controls and obese PCOS (P=0.003). 
 
 A simple linear regression was calculated to predict TNF and IL-1ß expression 
based on BMI for all study subjects. A significant regression equation was found (F(1,38) 









 A simple linear regression was calculated to predict TNF and IL-1ß expression 
based on BMI among women with PCOS. An insignificant regression equation was 
found (F(1,24) = 3.464, P=0.075), with an R2=0.126 for TNF and (F(1,24) = 2.881, 
P=0.101), with an R2=0.096 for IL-1ß. 
 
a b 
Figure 8. Correlation between BMI of women with PCOS and cytokine expression. 
a, TNF expression (P=0.075) and b, IL1ß expression (P=0.101). 
 
A simple linear regression was calculated to predict TNF and IL-1ß expression 
based on fasting glucose for all study subjects. A significant regression equation was 
found (F(1,37) = 5.214, P=0.028), with an R2=0.124. An insignificant regression 





Figure 9. Correlation between fasting glucose and cytokine expression. a, TNF 
expression (P=0.028) and b, IL-1ß expression (P=0.102). 
 
 A simple linear regression was calculated to predict TNF and IL-1ß expression 
based on fasting glucose for PCOS subjects. An insignificant regression equation was 
found (F(1,24) = 2.328, P=0.141, with an R2=0.092 for TNF and (F(1,24) = 1.625, 
P=0.214), with and R2=0.059 for IL-1ß. 
 
a b 
Figure 10. Correlation between fasting glucose of women with PCOS and Cytokine 




 Multiple linear regression analysis was calculated to predict TNF and IL-1ß 
expression based on BMI and fasting glucose among women with PCOS. An 
insignificant regression was found (F(2,22) = 2.329, P=0.121) for TNF, and R2=0.175, 
and (F(2,22) = 1.682, P=0.206), and R2=0.119 for IL-1ß. BMI and fasting glucose were 

















Polycystic ovarian syndrome is a common endocrine disorder in women of 
reproductive age and represents a complex pathophysiological model. Traditionally, 
PCOS has been characterized by the presence of excess androgens. However, excess 
androgens may be a secondary consequence of abnormal metabolic physiology. Obesity, 
a highly prevalent morbidity in women with PCOS, is well understood to contribute to an 
inflammatory environment leading to the development of insulin resistance. Although, a 
portion of women with PCOS remain who exhibit insulin resistance in the absence of 
obesity. Insulin resistance in the absence of obesity suggests an alternative mechanism 
mediating insulin sensitivity in women with PCOS. Recent evidence has suggested that 
that inflammatory dysregulation is a primary mediator leading to insulin resistance. 
Subsequent metabolic abnormalities resulting from impaired insulin sensitivity drives the 
clinical manifestation of excess androgens.  
The effect of adiposity and fasting glucose on mRNA expression of TNF and 
IL-1ß in MNCs was explored in women diagnosed with PCOS. Overexpression of both 
TNF and IL-1ß are widely known to contribute to the development of glucose 
intolerance, insulin resistance, and atherosclerosis [18-20]. Data from this study gives 
evidence that mRNA expression of both TNF and IL-1ß are increased in PCOS and 
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remains consistent with previous literature assaying protein. TNF and IL-1ß mRNA was 
found to positively correlate with BMI in all study subjects, suggesting that BMI is a 
significant contributor of inflammation. However, a significant increase in TNF and IL-
1ß mRNA was not observed when only comparing PCOS subjects. Limitations in sample 
size may contribute to this observation. Although, BMI does not account for the 
distribution of adipose tissue in the individual. Preferential android adipose distribution 
may potentially contribute to the increased inflammatory environment observed in PCOS. 
Correlations between fasting glucose and mRNA expression of TNF and IL-1ß 
were also explored. Fasting glucose was observed to have little impact on TNF and IL-ß 
mRNA expression in PCOS. However, a positive correlation was found between fasting 
glucose and TNF among all study subjects. Plasma glucose concentration is heavily 
dependent on insulin concentration, and may inaccurately represent glycemic status by 
lowering plasma glucose if insulin is elevated. An improved model of glycemic status, 
homeostatic model assessment of insulin resistance (HOMA-IR), accounts for both 
glucose and insulin concentration. 
Increased mRNA expression of TNF and IL-1ß gives evidence that an 
inflammatory phenotype is predominant in PCOS. Inflammatory signals promote and 
maintain differentiation of macrophage towards the M1 phenotype. Maintaining an 
inflammatory environment significantly contributes to the development of insulin 
resistance and subsequent metabolic aberrations observed in PCOS. 
Further research exploring inflammatory, and anti-inflammatory expression when 
challenged with a glucose load during a 3˚ glucose tolerance test may provide greater 
insight to the correlation between metabolic aberrations and inflammatory cytokine 
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expression. Inclusion of plasma insulin would provide a greater representation of 
glycemic status and insulin resistance of the subject. Also, measuring waist to hip 
circumference in addition to BMI may be a more significant indicator of adiposity than 
BMI alone. 
In summary, this study provides evidence that mRNA expression of TNF and 
IL-1ß is increased in women with PCOS. Therefore, inflammation is a significant 
pathophysiological component in PCOS that potentially plays a critical role in developing 




1. Roe, A.H. and A. Dokras, The Diagnosis of Polycystic Ovary Syndrome in 
Adolescents. Reviews in Obstetrics and Gynecology, 2011. 4(2): p. 45-51. 
2. Hart, R. and D.A. Doherty, The potential implications of a PCOS diagnosis on a 
woman's long-term health using data linkage. J Clin Endocrinol Metab, 2015. 
100(3): p. 911-9. 
3. Hoffman, B.L., et al., Polycystic Ovarian Syndrome and Hyperandrogenism, in 
Williams Gynecology, 3e. 2016, McGraw-Hill Education: New York, NY. 
4. Boyle, J. and H. Teede, Polycystic ovary syndrome An update. Australian Family 
Physician, 2012. 41: p. 752-756. 
5. Rojas, J., et al., Polycystic ovary syndrome, insulin resistance, and obesity: 
navigating the pathophysiologic labyrinth. Int J Reprod Med, 2014. 2014: p. 
719050. 
6. Setji, T.L. and A.J. Brown, Polycystic ovary syndrome: diagnosis and treatment. 
Am J Med, 2007. 120(2): p. 128-32. 
7. Escobar-Morreale, H.F., et al., Epidemiology, diagnosis and management of 
hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary 
Syndrome Society. Hum Reprod Update, 2012. 18(2): p. 146-70. 
8. Pellatt, L., S. Rice, and H.D. Mason, Anti-Mullerian hormone and polycystic 
ovary syndrome: a mountain too high? Reproduction, 2010. 139(5): p. 825-33. 
9. Pierre, A., et al., Loss of LH-induced down-regulation of anti-Mullerian hormone 
receptor expression may contribute to anovulation in women with polycystic 
ovary syndrome. Hum Reprod, 2013. 28(3): p. 762-9. 
10. Blank, S.K., C.R. McCartney, and J.C. Marshall, The origins and sequelae of 
abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod 
Update, 2006. 12(4): p. 351-61. 
11. Gonzalez, F., et al., The altered mononuclear cell-derived cytokine response to 
glucose ingestion is not regulated by excess adiposity in polycystic ovary 
syndrome. J Clin Endocrinol Metab, 2014. 99(11): p. E2244-51. 
12. Gonzalez, F., Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role 
in the Development of Metabolic Aberration and Ovarian Dysfunction. Semin 
Reprod Med, 2015. 33(4): p. 276-86. 
13. Jensen, M.D., et al., 2013 AHA/ACC/TOS Guideline for the Management of 
Overweight and Obesity in Adults. Circulation, 2014. 129(25 suppl 2): p. S102-
S138. 
14. Flegal, K.M., et al., Prevalence of obesity and trends in the distribution of body 
mass index among US adults, 1999-2010. JAMA, 2012. 307(5): p. 491-7. 
15. Carmina, E., et al., Abdominal fat quantity and distribution in women with 
polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin 
Endocrinol Metab, 2007. 92(7): p. 2500-5. 
16. Fauser, B.C., et al., Consensus on women's health aspects of polycystic ovary 
syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS 
Consensus Workshop Group. Fertil Steril, 2012. 97(1): p. 28-38 e25. 
 
 32 
17. Lord, J., et al., The central issue? Visceral fat mass is a good marker of insulin 
resistance and metabolic disturbance in women with polycystic ovary syndrome. 
BJOG, 2006. 113(10): p. 1203-9. 
18. Zhang, H., et al., Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond), 
2009. 116(3): p. 219-30. 
19. Willerson, J.T. and P.M. Ridker, Inflammation as a cardiovascular risk factor. 
Circulation, 2004. 109(21 Suppl 1): p. II2-10. 
20. Maedler, K., et al., Interleukin-1 beta targeted therapy for type 2 diabetes. Expert 
Opinion on Biological Therapy, 2009. 9(9): p. 1177-1188. 
21. Moganti, K., et al., Hyperglycemia induces mixed M1/M2 cytokine profile in 
primary human monocyte-derived macrophages. Immunobiology, 2016. 
22. Crowther, M., et al., Microenvironmental influence on macrophage regulation of 
angiogenesis in wounds and malignant tumors. Journal of Leukocyte Biology, 
2001. 70(4): p. 478-490. 
23. Kittan, N.A., et al., Cytokine induced phenotypic and epigenetic signatures are 
key to establishing specific macrophage phenotypes. PLoS One, 2013. 8(10): p. 
e78045. 
24. Rice, K.L., I. Hormaeche, and J.D. Licht, Epigenetic regulation of normal and 
malignant hematopoiesis. Oncogene, 2007. 26(47): p. 6697-714. 
25. McNelis, J.C. and J.M. Olefsky, Macrophages, immunity, and metabolic disease. 
Immunity, 2014. 41(1): p. 36-48. 
26. Olefsky, J.M. and C.K. Glass, Macrophages, inflammation, and insulin 
resistance. Annu Rev Physiol, 2010. 72: p. 219-46. 
27. Odegaard, J.I., et al., Alternative M2 activation of Kupffer cells by PPARdelta 
ameliorates obesity-induced insulin resistance. Cell Metab, 2008. 7(6): p. 496-
507. 
28. Goh, Y.P.S., et al., Eosinophils secrete IL-4 to facilitate liver regeneration. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2013. 110(24): p. 9914-9919. 
29. Wu, D., et al., Eosinophils sustain adipose alternatively activated macrophages 
associated with glucose homeostasis. Science, 2011. 332(6026): p. 243-7. 
30. Biswas, S.K. and A. Mantovani, Orchestration of metabolism by macrophages. 
Cell Metab, 2012. 15(4): p. 432-7. 
31. Daneman, D., et al., Insulin-Stimulated Glucose Transport in Circulating 
Mononuclear Cells From Nondiabetic and IDDM Subjects. Diabetes, 1992. 41(2): 
p. 227. 
32. Flier, J.S., et al., Impaired in Vivo Insulin Clearance in Patients With Severe 
Target-Cell Resistance to Insulin. Diabetes, 1982. 31(2): p. 132. 
33. Gao, Z., et al., Serine phosphorylation of insulin receptor substrate 1 by inhibitor 
kappa B kinase complex. J Biol Chem, 2002. 277(50): p. 48115-21. 
34. Zhang, J., et al., S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin 
resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem, 
2008. 283(51): p. 35375-82. 
35. Donath, M.Y. and S.E. Shoelson, Type 2 diabetes as an inflammatory disease. 
Nat Rev Immunol, 2011. 11(2): p. 98-107. 
 
 33 
36. Welty, F.K., A. Alfaddagh, and T.K. Elajami, Targeting inflammation in 
metabolic syndrome. Transl Res, 2016. 167(1): p. 257-80. 
37. Mohanty, P., et al., Glucose Challenge Stimulates Reactive Oxygen Species (ROS) 
Generation by Leucocytes. The Journal of Clinical Endocrinology & Metabolism, 
2000. 85(8): p. 2970-2973. 
38. Baptiste, C.G., et al., Insulin and hyperandrogenism in women with polycystic 
ovary syndrome. J Steroid Biochem Mol Biol, 2010. 122(1-3): p. 42-52. 
39. Lauretta, R., et al., Insulin-Sensitizers, Polycystic Ovary Syndrome and 
Gynaecological Cancer Risk. Int J Endocrinol, 2016. 2016: p. 8671762. 
40. Wu, S., et al., Obesity-Induced Infertility and Hyperandrogenism Are Corrected 
by Deletion of the Insulin Receptor in the Ovarian Theca Cell. Diabetes, 2014. 
63(4): p. 1270. 
41. Jamnongjit, M. and S.R. Hammes, Ovarian Steroids: The Good, the Bad, and the 
Signals that Raise Them. Cell cycle (Georgetown, Tex.), 2006. 5(11): p. 1178-
1183. 
42. Gonzalez, F., et al., Elevated serum levels of tumor necrosis factor alpha in 
normal-weight women with polycystic ovary syndrome. Metabolism, 1999. 48(4): 
p. 437-441. 
43. Dumesic, D.A., et al., Hyperandrogenism Accompanies Increased Intra-
Abdominal Fat Storage In Normal Weight Polycystic Ovary Syndrome Women. J 
Clin Endocrinol Metab, 2016: p. jc20162586. 
44. Gonzalez, F., et al., Evidence of mononuclear cell preactivation in the fasting 
state in polycystic ovary syndrome. Am J Obstet Gynecol, 2014. 211(6): p. 635 
e1-7. 
45. Jensterle Sever, M., et al., Short-term combined treatment with liraglutide and 
metformin leads to significant weight loss in obese women with polycystic ovary 
syndrome and previous poor response to metformin. Eur J Endocrinol, 2014. 
170(3): p. 451-9. 
46. Pfaffl, M.W., A new mathematical model for relative quantification in real-time 




























Sample Age (y) BMI (kg/m2) Glucose (mg/dL) 
A1 30 51.3 119 
A2 32 38.4 92 
A3 39 36.1 92 
A4 37 47.5 123 
A5 33 31.3 90 
A6 26 44.6 82 
A7 33 40.5 135 
A8 37 38.8 94 
A9 29 36.4 72 
A10 19 25.0 92 
A11 47 42.7 94 
A12 40 29.8 94 
A13 26 46.1 112 
A14 28 49.4 88 
A15 21 38.9 87 
A16 35 43.1 87 
A17 48 27.3 89 
A18 24 40.6 83 
A19 22 46.1 84 
A20 22 36.2 99 
A21 33 47.3 99 
A22 36 21.8 86 
A23 42 51.4 90 
A24 55 26.4 89 
A25 21 48.0 84 
B1 39 49.8 90 
B2 25 28.3 91 
B3 18 22.6 81 
B4 20 30.0 90 
B5 23 42.4 93 
B6 18 25.5 84 
B7 18 22.3 78 
B8 18 41.2 90 
B9 18 26.5 82 
B10 18 21.3 97 
B11 18 31.9 87 
B12 18 26.7 90 
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B13 20 25.1 87 
B14 18 26.6 87 
Appendix 1. Age, BMI, and fasting glucose 
 
